Department of Morphology, Surgery and Experimental Medicine, University of Ferrara, Ferrara, Italy.
Department of Ophthalmology, Ospedali Privati Forlì "Villa Igea", Forlì, Italy.
Br J Ophthalmol. 2021 Dec;105(12):1651-1655. doi: 10.1136/bjophthalmol-2020-317253. Epub 2020 Oct 3.
BACKGROUND/AIMS: To report the 10-year outcomes of modified microkeratome-assisted lamellar keratoplasty (LK) for keratoconus.
In this single-centre interventional case series, 151 consecutive eyes with keratoconus underwent modified microkeratome-assisted LK. Eyes with scars extending beyond the posterior half of the corneal stroma and preoperative thinnest-point pachymetry value of less than 300 μm were excluded. Outcome measures were best spectacle-corrected visual acuity (BSCVA), refractive astigmatism (RA), endothelial cell density, immunological rejection, ectasia recurrence and graft failure rates.
Baseline BSCVA (0.89±0.31 logarithm of the minimum angle of resolution (logMAR)) significantly improved to 0.10±0.12 logMAR at year 3 (p<0.001), and remained stable up to 10 years. At 10 years, 94% of eyes saw ≥20/40, 61% saw ≥20/25 and 24% saw ≥20/20 Snellen BSCVA. At final follow-up, RA exceeding 4.5 dioptres was observed in 5 cases (4%). Endothelial cell loss was 25±17% at 1 year with an annual decline of 2% over 10 years. The 10-year cumulative risk for immunological rejection and graft failure was 8.5%, and 2.4%, respectively. No case developed recurrent ectasia at 10 years.
Modified microkeratome-assisted LK results in stable visual and refractive outcomes with low rates of immunological rejection and graft failure in the absence of recurrence of ectasia for at least 10 years.
背景/目的:报告角膜交联术联合改良微型角膜刀辅助板层角膜移植术治疗圆锥角膜的 10 年结果。
在这项单中心的干预性病例系列研究中,对 151 例连续的圆锥角膜患者进行了改良微型角膜刀辅助板层角膜移植术。排除了角膜后基质半区存在瘢痕和术前最薄点角膜厚度值小于 300 μm的患者。观察指标包括最佳矫正视力(BCVA)、屈光性散光(RA)、角膜内皮细胞密度、免疫排斥反应、扩张复发和移植物失败率。
基线时 BCVA(0.89±0.31 最小分辨角对数(logMAR))在第 3 年显著提高至 0.10±0.12 logMAR(p<0.001),并稳定至 10 年。在 10 年时,94%的患者视力≥20/40,61%的患者视力≥20/25,24%的患者视力≥20/20 Snellen BCVA。最终随访时,5 例(4%)患者出现超过 4.5 屈光度的 RA。术后 1 年角膜内皮细胞丢失率为 25±17%,10 年内每年下降 2%。10 年免疫排斥和移植物失败的累积风险分别为 8.5%和 2.4%。10 年内无病例出现扩张复发。
改良微型角膜刀辅助板层角膜移植术可获得稳定的视力和屈光结果,在 10 年内免疫排斥和移植物失败的发生率低,且无扩张复发。